Visualitzant O - Articles científics per títol

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Marchetti, Monia; Salmanton‑García, Jon; Verga, Luisa; Ráčil, Zdeněk; Jimenez Balarezo, Moraima; Cabirta Touzon, Alba; Itri, Federico; El-Ashwah, Shaimaa (SAGE Publications, 2023)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Serna-Blasco, Roberto; Garcia‑Campelo, Rosario; Casal Rubio, Joaquín; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest (American Society of Clinical Oncology, 2022-09-01)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Michels, Sebastian; Vasyliv, I.; Stratmann, Jan Alexander; Frank, Julia; Adams, Alexandra M.; Massuti, Bartomeu; FELIP, ENRIQUETA (Elsevier, 2024-02)

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Geyer, C. E. Jr; Garber, J. E.; Gelber, R. D.; Yothers, Greg; Taboada, M.; Ross, L.; Balmaña Gelpí, Judith (Elsevier, 2022-12)

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

DiSilvestro, Paul; Kim, Byoung-Gie; Oaknin Benzaquen, Ana Mazaltob; Scambia, Giovanni; Banerjee, Susana; Colombo, Nicoletta (American Society of Clinical Oncology, 2023-01-20)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

Iranzo Gómez, Patricia; Callejo Perez, Ana; Assaf Pastrana, Juan David; Molina, Gaspar; Lopez, Daniel Esteban; García Illescas, David; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martínez Marti, Alexandre; Cedres Perez, Susana; Amat, Ramon; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan (Frontiers Media, 2022-05-30)

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies

Lorini, Luigi; Bescós Atin, Coro; Thavaraj, Selvam; Müller-Richter, Urs; Alberola Ferranti, Margarita; Pamias Romero, Jorge; Saez barba, Manuel; Braña Garcia, Irene; Nuciforo, Paolo Giovanni; Simonetti, Sara; De Pablo García-Cuenca, Alba (MDPI, 2021-08)

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Mouron, Silvana; Bueno, MJ; Muñoz, Manuel; Torres, Raul; Rodriguez, Sandra; Apala, Juan V.; Malumbres Martinez, Marcos (Oxford University Press, 2023-04)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Ahmad Diaz, Faten; Villanueva, Rafael; Valdivia Vadell, Carolina; Palomino-Doza, Julián; Ruiz, Ada; Azaro Pedrazzoli, Analía Beatriz; Aguilar Company, Juan; Martín Pérez, Anastasio; Escriva de Romaní Muñoz, Santiago Ignacio; Alcalde Rodrigo, Maria; Ruiz Camps, Isabel; Bellet Ezquerra, Meritxell; Reyes López, Victoria (SAGE Publications, 2019-05-10)

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Albanell, Joan; Pérez-García, José Manuel; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Comerma Blesa, Laura; Bellet Ezquerra, Meritxell; Curigliano, Giuseppe (American Association for Cancer Research, 2023-01-04)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pérez-García, José Manuel; Dalenc, Florence; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Di Cosimo, Serena; Bellet Ezquerra, Meritxell (Oxford University Press, 2023-01)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Koppikar, Smruti; OAKNIN, ANA; Babu, K. Govind; Lorusso, Domenica; Gupta, S.; Wu, L.-Y. (Elsevier, 2023-02)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Westphalen, C Benedikt; Fine, Alexander D.; André, Fabrice; Ganesan, Shridar; Heinemann, Volker; Rouleau, Etienne; Mateo Valderrama, Joaquim (American Association for Cancer Research, 2022-04-01)

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Cassier, Phillippe A.; Siena , Salvatore; Garralda Cabanas, Elena; Paz-Ares, Luis; Garrido, Pilar; Subbiah, Vivek (Nature Research, 2022-08)

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Movasati, Ali; Brunner, Sascha Remy; Nguyen, Luan; Van Hoeck, Arne; Martínez-Jiménez, Francisco; Priestley, Peter; Cuppen, Edwin (Nature Portfolio, 2023-06)

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Oza, Amit M.; Lorusso, Domenica; Oaknin Benzaquen, Ana Mazaltob; Dean, Andrew; Colombo, Nicoletta; Aghajanian, Carol (American Society of Clinical Oncology, 2020-10-20)

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Hernando-Calvo, Alberto; GARRALDA, Elena (American Association for Cancer Research, 2023-08-04)

Patient-derived preclinical models to develop immunotherapies

Seoane, Joan (Wiley, 2023-07)

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Kim, Hye Ryun; Gottfried, Maya; Peters, Solange; Csoszi, Tibor; Awad, Mark; NAVARRO, ALEJANDRO (Elsevier, 2023-11)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Harrison, Claire; McLornan, Donal; McMullin, Mary Frances; mesa, ruben; Palmer, Jeanne; Fox, Maria Laura; Gupta, Vikas (Wolters Kluwer Health, 2023-11)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Patient-derived preclinical models to develop immunotherapies

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry ﻿

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial) ﻿

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial ﻿

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer ﻿

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ﻿

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer ﻿

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies ﻿

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer ﻿

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication ﻿

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial ﻿

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial ﻿

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer ﻿

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score ﻿

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial ﻿

Pan-cancer whole-genome comparison of primary and metastatic solid tumours ﻿

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma ﻿

Patient-Centric Approaches for Phase I Combination Trials Come on Stage ﻿

Patient-derived preclinical models to develop immunotherapies ﻿

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC ﻿

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Patient-derived preclinical models to develop immunotherapies

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study